Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX464 in Moderately to Severely Active Ulcerative Colitis
NCT05507203Phase 3Completed
- Sponsor
- Abivax
- Start
- Nov 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of obefazimod in ulcerative colitis (UC), sponsored by Abivax. Started Nov 2022; status: completed.
02
Drugs
obefazimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05507203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507203.